Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial

被引：15

作者：

Hauswald, Henrik ^{[1
]}

Habl, Gregor ^{[1
]}

Krug, David ^{[1
]}

Kehle, Denise ^{[1
]}

Combs, Stephanie E. ^{[1
]}

Bermejo, Justo Lorenzo ^{[2
]}

Debus, Juergen ^{[1
]}

Sterzing, Florian ^{[1
]}

机构：

[1] Univ Heidelberg Hosp, Dept Radiat Oncol, D-69120 Heidelberg, Germany

[2] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany

来源：

RADIATION ONCOLOGY | 2013年 / 8卷

关键词：

Malignant melanoma; Brain metastases; Radiotherapy; Tomotherapy; Integrated boost; NERVOUS-SYSTEM METASTASES; CEREBRAL METASTASES; PROGNOSTIC-FACTORS; RADIATION-THERAPY; RADIOSURGERY; RADIOTHERAPY; SURVIVAL;

D O I：

10.1186/1748-717X-8-234

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Patients with malignant melanoma may develop brain metastases during the course of the disease, requiring radiotherapeutic treatment. In patients with 1-3 brain metastases, radiosurgery has been established as a treatment option besides surgery. For patients with 4 or more brain metastases, whole brain radiotherapy is considered the standard treatment. In certain patients with brain metastases, radiation treatment using whole brain helical Tomotherapy with integrated boost and hippocampal-sparing may improve prognosis of these patients. Methods/Design: The present prospective, randomized two-armed trial aims to exploratory investigate the treatment response to conventional whole brain radiotherapy applying 30 Gy in 10 fractions versus whole brain helical Tomotherapy applying 30 Gy in 10 fractions with an integrated boost of 50 Gy to the brain metastases as well as hippocampal-sparing in patients with brain metastases from malignant melanoma. The main inclusion criteria include magnetic resonance imaging confirmed brain metastases from a histopathologically confirmed malignant melanoma in patients with a minimum age of 18 years. The main exclusion criteria include a previous radiotherapy of the brain and not having recovered from acute high-grade toxicities of prior therapies. The primary endpoint is treatment-related toxicity. Secondary endpoints include imaging response, local and loco-regional progression-free survival, overall survival and quality of life.

引用

页数：6

共 38 条

[1]

AMER MH, 1978, CANCER-AM CANCER SOC, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO

[2]

2-E

[3]

[Anonymous], KREBS DEUTSCHL 2007

[4] Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience [J].

Awad, Raef ;

Fogarty, Gerald ;

Hong, Angela ;

Kelly, Patricia ;

Ng, Diana ;

Santos, Daniel ;

Haydu, Lauren .

RADIATION ONCOLOGY, 2013, 8

[5] Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients [J].

Broadbent, AM ;

Hruby, G ;

Tin, MM ;

Jackson, M ;

Firth, I .

RADIOTHERAPY AND ONCOLOGY, 2004, 71 (03) :259-265

[6] Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma - A retrospective study [J].

Buchsbaum, JC ;

Suh, JH ;

Lee, SY ;

Chidel, MA ;

Greskovich, JF ;

Barnett, GH .

CANCER, 2002, 94 (08) :2265-2272

[7] CURRENT CAUSES OF DEATH IN PATIENTS WITH MALIGNANT-MELANOMA [J].

BUDMAN, DR ;

CAMACHO, E ;

WITTES, RE .

EUROPEAN JOURNAL OF CANCER, 1978, 14 (04) :327-330

[8] CENTRAL NERVOUS-SYSTEM METASTASES IN MALIGNANT-MELANOMA [J].

BULLARD, DE ;

COX, EB ;

SEIGLER, HF .

NEUROSURGERY, 1981, 8 (01) :26-30

[9]

CHOI KN, 1985, CANCER-AM CANCER SOC, V56, P1, DOI 10.1002/1097-0142(19850701)56:1<1::AID-CNCR2820560102>3.0.CO

[10]

2-X

← 1 2 3 4 →